Gilead Sciences and its subsidiary Kite have partnered with Pfizer on the development of a new treatment regimen for large B-cell lymphoma.
The companies will partner to evaluate the safety and efficacy of an investigational combination of Kite's Yescarta and Pfizer's utomilumab, a fully humanised 4-1BB agonist monoclonal antibody, in patients with refractory large B-cell lymphoma.
“Gilead Sciences and Kite are partnering with Pfizer to assess a promising new combination treatment for refractory large B-cell lymphoma.“
A multi-centre phase I/II study sponsored by Kite is expected to begin this year, with the results of this study to be used to evaluate options for further development of this combination, or similar combinations involving utomilumab and Kite therapies.
Yescarta is the first CAR-T cell therapy to be indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, while utomilumab has been shown in preclinical models to enhance T-cell-mediated immune responses.
Dr David Chang, worldwide head of research and development and chief medical officer at Kite, said: "We are pleased to collaborate with Pfizer on this study with utomilumab, which adds to the growing number of combination approaches we are exploring with Yescarta for patients living with lymphoma."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical